Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs
- 9 July 2010
- journal article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 29 (6), 1414-1419
- https://doi.org/10.1007/s10637-010-9490-7
Abstract
Dose-limiting toxicity (DLT) remains the preferred metric in dose-finding phase 1 trials. Nevertheless, this primary endpoint appears unsuitable for investigating non-cytotoxic drugs. We reviewed 201 recent dose-finding phase 1 trials and compared the DLT defined with cytotoxic (119 trials) and non-cytotoxic drugs (molecular-targeted therapies and immune-stimulant agents; 82 trials). DLT was less frequently identified with non-cytotoxic drugs (52 vs. 89%, p = 0.00005). Myelotoxicity remains the most frequent DLT in studies investigating cytotoxic agents (51%). Myelotoxicity was significantly less frequent in studies investigating non-cytotoxic drugs (14%, p = 0.00003). Skin toxicities (p = 0.038), coagulation perturbation (p = 0.025) and fever (p = 0.025) were the most frequent DLTs in studies investigating non-cytotoxic drugs. Moreover, DLTs identified with non-cytotoxic drugs were less frequently objectively measurable as they were based on biological anomalies (30 vs. 63%, p = 0.0026). Approximately 50% of dose-finding phase 1 trials investigating non-cytotoxic drugs led to DLT and then the maximum tolerated dose being found. However, the nature of these DLTs is different from those described with cytotoxic drugs and less objectively measurable in many cases.Keywords
This publication has 11 references indexed in Scilit:
- Proposal for size justification of expanded cohort at phase-2-recommended doseInvestigational New Drugs, 2010
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI Journal of the National Cancer Institute, 2009
- “Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agentsInvestigational New Drugs, 2009
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor ActivityJournal of Clinical Oncology, 2008
- Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)European Journal of Cancer, 2008
- Ethical and Design Issues of Phase I Clinical Trials in Cancer PatientsCancer Investigation, 2007
- Methodology of clinical trials with new molecular-targeted agents: where do we stand?Annals Of Oncology, 2006
- Dose escalation trial designs based on a molecularly targeted endpointStatistics in Medicine, 2005
- The Limited Precision of Phase I TrialsJNCI Journal of the National Cancer Institute, 1994
- Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer AgentsJNCI Journal of the National Cancer Institute, 1993